155
Participants
Start Date
July 20, 2020
Primary Completion Date
May 19, 2023
Study Completion Date
June 18, 2023
Dose-Placebo
Unit Dose Strength - 0.9%.
Low Dose-VIS649
Dose Level = Low
Medium Dose-VIS649
Dose Level = Medium
High Dose-VIS649
Dose Level = High
Visterra Investigational Site, Colombo
Visterra Investigational Site, Diliman
Visterra Investigational Site, Quezon City
Visterra Investigational Site, Saint Leonards
Visterra Investigational Site, New Lambton Heights
Visterra Investigational Site, Seoul
Visterra Investigational Site, Seoul
Visterra Investigational Site, Nambour
Visterra Investigational Site, Gangdong
Visterra Investigational Site, Nedlands
Visterra Investigational Site, Barcelona
Visterra Investigational Site, L'Hospitalet de Llobregat
Visterra Investigational Site, New York
Visterra Investigational Site, Bangkok
Visterra Investigational Site, Ratchathewi
Visterra Investigational Site, Seongnam-si
Visterra Investigational Site, Córdoba
Visterra Investigational Site, Anyang-si
Visterra Investigational Site, Bethlehem
Visterra Investigational Site, Hwaseong-si
Visterra Investigational Site, Kandy
Visterra Investigational Site, Keelung
Visterra Investigational Site, New Taipei City
Visterra Investigational Site, New Taipei City
Visterra Investigational Site, Kuantan
Visterra Investigational Site, Chapel Hill
Visterra Investigational Site, Madrid
Visterra Investigational Site, Lawrenceville
Visterra Investigational Site, Birmingham
Visterra Investigational Site, Tupelo
Visterra Investigational Site, Santander
Visterra Investigational Site, Xitun
Visterra Investigational Site, Seville
Visterra Investigational Site, Seville
Visterra Investigational Site, Klang
Visterra Investigational Site, Columbus
Visterra Investigational Site, Valencia
Visterra Investigational Site, Chiang Mai
Visterra Investigational Site, Kuala Lumpur
Visterra Investigational Site, Kuala Lumpur
Visterra Investigational Site, Seremban
Visterra Investigational Site, Baton Rouge
Visterra Investigational Site, Denver
Visterra Investigational Site, Kaohsiung City
Visterra Investigational Site, Kaohsiung City
Visterra Investigational Site, Oxnard
Visterra Investigational Site, Palo Alto
Visterra Investigational Site, New Delhi
Visterra Investigational Site, Chandigarh
Visterra Investigational Site, Singapore
Visterra Investigational Site, Raebareli
Visterra Investigational Site, Singapore
Visterra Investigational Site, Hyderabad
Visterra Investigational Site, Hyderabad
Visterra Investigational Site, Bengaluru
Visterra Investigational Site, Bangalore
Visterra Investigational Site, Manipal
Visterra Investigational Site, Vellore
Visterra Investigational Site, Kozhikode
Visterra Investigational Site, Thiruvananthapuram
Visterra Investigational Site, Kowloon
Visterra Investigational Site, Los Angeles
Visterra Investigational Site, Stanford
Visterra Investigational Site, New Orleans
Visterra Investigational Site, Baltimore
Visterra Investigational Site, Houston
Visterra Investigational Site, Houston
Visterra Investigational Site, Calgary
Visterra Investigational Site, Brampton
Visterra Investigational Site, Montreal
Visterra Investigational Site, Hong Kong
Visterra Investigational Site, Hong Kong
Visterra Investigational Site, Tsuen Wan
Visterra Investigational Site, Nugegoda
Visterra Investigational Site, Toyoake-shi
Visterra Investigational Site, Minatoku
Visterra Investigational Site, Tokyo
Visterra Investigational Site, Ashikaga
Visterra Investigational Site, Ashikaga-Shi
Visterra Investigational Site, Bunkyō City
Visterra Investigational Site, Kashihara-shi
Visterra Investigational Site, Niigata
Visterra Investigational Site, Shinjuku-Ku
Visterra Investigational Site, Tsukuba
Visterra Investigational Site, Urayasu-Shi
Visterra Investigational Site, Seoul
Visterra Investigational Site, Anyang
Visterra Investigational Site, Seoul
Visterra Investigational Site, Bradford
Visterra Investigational Site, London
Visterra Investigational Site, London
Visterra Investigational Site, London
Visterra Investigational Site, Salford
Visterra, Inc.
INDUSTRY